march corporate update, page-22

The US is in a Biotech boom , SSH is trading like a miner. Someone is accountable for the market cap despite we being told by management we have a product achieving outstanding results. Word of mouth should have spread out amongst those needing such treatment and ringing the company where they can get it. I know they are hiring a PR firm but the market investors in a Biotech boom should have SSH valued much much higher. As i mentioned before will heart failure treatment by C-Pulse impact THOR and HTWR valuations, would they rather see SSH disappear off the radar.